Germany proposed sweeping healthcare cost-cutting reforms aimed at reducing a projected €40 billion deficit in the country’s public health insurance system, raising concerns across the pharmaceutical and healthcare sectors.

 The chief executive of Acadia Pharmaceuticals has warned that President Donald Trump's "most favoured nation" pricing policy risks undermining the international research collaborations that have underpinned drug discovery for decades, in the latest sign of mounting industry concern over the regulatory and commercial direction of US pharmaceutical policy.

Neimeth International Pharmaceuticals, one of Nigeria's longest-established drugmakers, posted strong revenue growth in the first quarter of 2026, continuing a turnaround that has lifted the Lagos-listed group out of three years of losses — even as escalating finance costs and an entrenched debt load underscore how challenging the operating environment remains for the country's pharmaceutical industry.

Kazakhstan has approved an investment agreement underpinning a 42.5bn tenge (around $80mn) pharmaceutical production complex in the central region of Karaganda, in the latest step of a state-driven campaign to reduce the country's reliance on imported medicines and build a domestic manufacturing base in higher-value therapeutic categories.

Marty Makary has resigned as commissioner of the US Food and Drug Administration after months of internal turmoil, with White House staff having signed off on a plan to replace him last week.

Takeda Pharmaceutical (TAK) plans to eliminate around 4,500 jobs in fiscal year 2026 as part of a restructuring programme aimed at centralising corporate functions and reducing costs, the Japanese drugmaker said on Wednesday.

Rigel Pharmaceuticals has agreed to acquire exclusive global rights to Veppanu, the first FDA-approved therapy in a new class of cancer drugs that destroys disease-causing proteins rather than blocking them, paying $85mn upfront to Arvinas and Pfizer in a deal that materially repositions the South San Francisco-based group as a specialist commercial player in protein degradation oncology.

Milestone Pharmaceuticals, the dual-listed Canadian-US cardiovascular biotech, reported early commercial momentum for its newly launched nasal-spray heart rhythm therapy and confirmed the start of a late-stage trial in a second, larger indication, as it heads into the most operationally intensive phase in its corporate history.

Mira Pharmaceuticals, a small US clinical-stage biotech, has published peer-reviewed preclinical data for its experimental oral drug candidate SKNY-1, a compound being developed simultaneously as a treatment for obesity and nicotine addiction — a dual ambition that reflects the growing biological convergence between metabolic and addiction medicine.

EU member states have agreed to stockpile essential medicines and subsidise domestic production of key drugs in an effort to end persistent shortages and reduce dependence on imports from China and India.

Eli Lilly (LLY) has paused an obesity awareness campaign in India after the country's drugs regulator warned the company it may be breaching rules against advertising prescription medicines to consumers, even indirectly.

Polpharma, Poland's largest pharmaceutical group, has agreed to launch a voluntary public tender offer for Romanian drugmaker Biofarm at a valuation of approximately €270mn, marking one of the most significant cross-border consolidation moves in the central and eastern European pharmaceutical sector in recent years.

Analysts have cut their earnings forecasts for Fine Foods & Pharmaceuticals N.T.M., the Italian contract development and manufacturing group, after a first-quarter result that came in broadly in line with expectations but failed to prevent a sharp pullback in the share price.

GSK has struck an exclusive partnership with Hong Kong-listed Sino Biopharmaceutical to accelerate the launch of bepirovirsen, its closely watched experimental treatment for chronic hepatitis B, in mainland China — the largest single market for the disease and one of the most strategically significant geographies for what would be a first-in-class functional cure.

A New Jersey appeals court has revived whistleblower claims brought by a former compliance attorney at Novartis, reopening a case centred on alleged retaliation tied to internal compliance concerns.

The appellate court ruled that Cynthia Ham plausibly alleged a continuing pattern of retaliation under New Jersey’s Conscientious Employee Protection Act (CEPA), reversing an earlier decision that dismissed several claims as time-barred.

Capricor Therapeutics has filed a lawsuit against Nippon Shinyaku and its U.S. subsidiary NS Pharma over a dispute tied to the future commercialisation of experimental Duchenne muscular dystrophy therapy Deramiocel.

A U.S. appeals court hearing over Medicare drug price negotiations has added to mounting pressure on pharmaceutical companies challenging the Inflation Reduction Act’s pricing regime.

During oral arguments before the D.C. Circuit, judges appeared sceptical of arguments brought by Teva Pharmaceuticals over how regulators classify medicines for Medicare price negotiations.

Alto Neuroscience is seeking to dismiss an investor lawsuit accusing the psychiatric biotech company of overstating the prospects of its lead depression drug candidate, Alto-100.

According to investors, the trial was negatively affected by patients who falsely reported taking the medication, raising questions about the reliability of the results and the company’s earlier public statements about the drug’s prospects.

A French court has handed Millennium Pharmaceuticals, Janssen and Cilag a partial victory in their ongoing dispute with several generic drugmakers over the cancer treatment Velcade, allowing the case to move forward on the question of damages.

The FDA is intensifying enforcement against misleading pharmaceutical advertising, particularly online promotions, and recently issued a cease-and-desist letter to Alnylam Pharmaceuticals over claims made about Amvuttra, a drug for ATTR-CM.